Business Description
AtriCure Inc
NAICS : 339112
SIC : 3841
ISIN : US04963C2098
Total Employee Number:
1,350Description
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.26 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | 2.89 | |||||
Interest Coverage | 2.99 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 7.42 | |||||
Beneish M-Score | -2.91 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 15.7 | |||||
3-Year EPS without NRI Growth Rate | 52.4 | |||||
3-Year Book Growth Rate | 0.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 12.6 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 63.12 | |||||
9-Day RSI | 63.3 | |||||
14-Day RSI | 63.47 | |||||
3-1 Month Momentum % | -3.42 | |||||
6-1 Month Momentum % | -27.62 | |||||
12-1 Month Momentum % | -6.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.22 | |||||
Quick Ratio | 3.19 | |||||
Cash Ratio | 2.05 | |||||
Days Inventory | 215.66 | |||||
Days Sales Outstanding | 44.46 | |||||
Days Payable | 71.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.3 | |||||
Shareholder Yield % | 0.72 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 76.3 | |||||
Operating Margin % | 2.26 | |||||
Net Margin % | 1.85 | |||||
EBITDA Margin % | 4.51 | |||||
FCF Margin % | 8.36 | |||||
OCF Margin % | 11.3 | |||||
ROE % | 2.16 | |||||
ROA % | 1.64 | |||||
ROIC % | 2.51 | |||||
3-Year ROIIC % | 190.36 | |||||
ROC (Joel Greenblatt) % | 11.51 | |||||
ROCE % | 2.72 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 174.02 | |||||
Forward PE Ratio | 474.6 | |||||
PE Ratio without NRI | 158.89 | |||||
PS Ratio | 3.11 | |||||
PB Ratio | 3.58 | |||||
Price-to-Tangible-Book | 7.76 | |||||
Price-to-Free-Cash-Flow | 36.62 | |||||
Price-to-Operating-Cash-Flow | 27.11 | |||||
EV-to-EBIT | 113.82 | |||||
EV-to-Forward-EBIT | 554.62 | |||||
EV-to-EBITDA | 68.34 | |||||
EV-to-Forward-EBITDA | 19.07 | |||||
EV-to-Revenue | 3.08 | |||||
EV-to-Forward-Revenue | 2.78 | |||||
EV-to-FCF | 36.88 | |||||
Price-to-GF-Value | 0.91 | |||||
Price-to-Projected-FCF | 11.67 | |||||
Price-to-Median-PS-Value | 0.66 | |||||
Price-to-Graham-Number | 7.42 | |||||
| Price-to-Net-Current-Asset-Value | 10.01 | |||||
| Price-to-Net-Cash | 244.27 | |||||
Earnings Yield (Greenblatt) % | 0.88 | |||||
FCF Yield % | 2.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ATRC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AtriCure Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 569.622 | ||
| EPS (TTM) ($) | 0.21 | ||
| Beta | 1.2899 | ||
| 3-Year Sharpe Ratio | -0.36 | ||
| 3-Year Sortino Ratio | -0.51 | ||
| Volatility % | 24.83 | ||
| 14-Day RSI | 63.47 | ||
| 14-Day ATR ($) | 1.48445 | ||
| 20-Day SMA ($) | 33.05775 | ||
| 12-1 Month Momentum % | -6.26 | ||
| 52-Week Range ($) | 25.36 - 43.18 | ||
| Shares Outstanding (Mil) | 50.64 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AtriCure Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AtriCure Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-29 16:30 | In 95 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 94 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-23 16:30 | 33.52 (-2.84%) | ||
| Second quarter earnings results for 2026 | 2026-07-23 | 33.52 (-2.84%) | ||
| Goldman Sachs 47th Annual Global Health Care Conference | 2026-06-10 08:40 | 27.30 (+1.26%) | ||
| General meeting for 2026 | 2026-05-18 11:00 | 28.12 (-0.81%) | ||
| Guidance call for 2026 | 2026-05-12 10:00 | 26.30 (-0.15%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 16:30 | 28.78 (+0.24%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 28.78 (+0.24%) | ||
| Citizens Life Sciences Conference | 2026-03-10 13:05 | 29.38 (-1.44%) |
Show
Entries
AtriCure Inc Frequently Asked Questions
What is AtriCure Inc(ATRC)'s stock price today?
The current price of ATRC is $36.55. The 52 week high of ATRC is $43.18 and 52 week low is $25.36.
When is next earnings date of AtriCure Inc(ATRC)?
The next earnings date of AtriCure Inc(ATRC) is 2026-10-29 Est..
Does AtriCure Inc(ATRC) pay dividends? If so, how much?
AtriCure Inc(ATRC) does not pay dividend.
Guru Commentaries on NAS:ATRC
No articles.
Press Release
Articles on AtriCure Inc
Headlines
See More- 1
Jul 24, 2026
AtriCure targets $602M-$610M 2026 revenue while raising adjusted EBITDA outlook to $85M-$89M
Seeking Alpha • 8:41pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers